People · Operator
Named in public records as an officer, director or promoter · active 2015–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aura Biosciences, Inc. | — | Biotechnology | Series C | $198.2M | $2.5B | 2015 |
| Reneo Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $159.4M | $519.3M | 2019 |
| OrphoMed, Inc. | — | Biotechnology | Series B | $24.6M | $864.1M | 2017 |
Art Pappas at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Art Pappas on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Michael Martin | 1 | 11 |
| Ed Mathers | 1 | 11 |
| Peter B. Finn | 1 | 11 |
| Michael Grey | 1 | 10 |
| Niall O'Donnell | 1 | 7 |
| Casper Breum | 1 | 5 |
| Scott Weiner | 1 | 4 |
| Lawrence C. Best | 1 | 4 |
| Kenneth Harrison | 1 | 4 |
| Bali Muralidhar | 1 | 3 |
| Pedro Granadillo | 1 | 3 |
| Edward T. Mathers | 1 | 3 |
| Frank Torti | 1 | 3 |
| Alan Walts | 1 | 3 |
| Javier Garcia | 1 | 3 |
| Peter Wirth | 1 | 3 |
| Michael G. Grey | 1 | 2 |
| Edmundo Muniz, M.D., Ph.D. | 1 | 2 |
| Henri E. Termeer | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.